Complete Filing Data
Profound Medical Corp. reported Research And Development Expense of $20.60 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Profound Medical Corp. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Net Income * | -$42.6M | -$27.8M | -$28.3M |
| Research And Development Expense | $20.6M | $17.0M | $14.4M |
| Gross Profit | $11.4M | $7.0M | $4.3M |
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | $2.3M | -$2.8M | $644.0K |
| Selling General And Administrative Expense | $32.1M | $23.1M | $18.5M |
| Revenues | $16.1M | $10.7M | $7.2M |
| Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax | $0.00 | $0.00 | |
| Operating Income Loss | -$41.3M | -$33.1M | -$28.7M |
| Operating Expenses | $52.6M | $40.1M | $33.0M |
| Nonoperating Income Expense | -$1.1M | $5.2M | $200.0K |
| Interest Income Expense Nonoperating Net | $1.1M | $1.4M | $775.0K |
| Income Tax Expense Benefit | $252.0K | -$2.0K | -$128.0K |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$42.3M | -$27.8M | -$28.5M |
| Current Income Tax Expense Benefit | $231.0K | $144.0K | -$187.0K |
| Cost Of Revenue | $4.7M | $3.6M | $2.9M |
| Comprehensive Income Net Of Tax | -$40.3M | -$30.6M | -$27.7M |
| Amortization Of Intangible Assets | $187.0K | $229.0K | $202.0K |
| Revenue | $16.1M | $10.7M | $7.2M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|
| Net Income * | -$8.0M | -$15.7M | -$10.7M | -$9.4M | -$6.9M | -$6.6M |
| Research And Development Expense | $5.4M | $6.1M | $4.8M | $4.2M | $4.2M | $3.9M |
| Gross Profit | $3.9M | $1.6M | $1.9M | $1.8M | $1.4M | $866.0K |
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | -$808.0K | $2.7M | $103.0K | $584.0K | -$470.0K | -$969.0K |
| Selling General And Administrative Expense | $7.4M | $9.3M | $8.2M | $6.6M | $5.1M | $4.8M |
| Revenues | $5.3M | $2.2M | $2.6M | $2.8M | $2.2M | $1.4M |
| Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income Loss | -$8.9M | -$13.8M | -$11.2M | -$9.0M | -$7.8M | -$7.9M |
| Operating Expenses | $12.8M | $15.4M | $13.0M | $10.8M | $9.3M | $8.7M |
| Nonoperating Income Expense | $1.1M | -$1.8M | $483.0K | -$190.0K | $942.0K | $1.3M |
| Interest Income Expense Nonoperating Net | $122.0K | $343.0K | $445.0K | $220.0K | $422.0K | $462.0K |
| Income Tax Expense Benefit | $121.0K | $64.0K | $41.0K | $177.0K | $19.0K | $40.0K |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$7.9M | -$15.6M | -$10.7M | -$9.2M | -$6.9M | -$6.5M |
| Current Income Tax Expense Benefit | $100.0K | $78.0K | $41.0K | $177.0K | $19.0K | $40.0K |
| Cost Of Revenue | $1.4M | $593.0K | $768.0K | $1.0M | $812.0K | $573.0K |
| Comprehensive Income Net Of Tax | -$8.8M | -$13.0M | -$10.6M | -$8.8M | -$7.4M | -$7.6M |
| Amortization Of Intangible Assets | $47.0K | $51.0K | ||||
| Revenue | $5.3M | $2.2M | $2.6M | $2.8M | $2.2M | $1.4M |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Stockholders Equity | $66.4M | $60.4M | $31.2M | $52.6M |
| Liabilities | $11.0M | $9.8M | $12.7M | |
| Assets | $77.5M | $70.2M | $44.0M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $59.7M | $54.9M | $26.2M | $46.5M |
| Equity | $66.4M | $60.4M | $31.2M | $52.6M |
| Repayments Of Long Term Debt | $290.0K | $912.0K | ||
| Retained Earnings Accumulated Deficit | -$287.7M | -$245.2M | -$217.4M | |
| Property Plant And Equipment Net | $698.0K | $425.0K | $909.0K | |
| Other Liabilities Noncurrent | $79.0K | $71.0K | $73.0K | |
| Operating Lease Right Of Use Asset | $184.0K | $396.0K | $661.0K | |
| Operating Lease Liability Current | $213.0K | $257.0K | $259.0K | |
| Non Cash Lease Expense Adjustment | $37.0K | $38.0K | $45.0K | |
| Liabilities Current | $6.1M | $6.6M | $6.4M | |
| Liabilities And Stockholders Equity | $77.5M | $70.2M | $44.0M | |
| Inventory Net | $8.2M | $5.8M | $7.0M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|
| Stockholders Equity | $32.1M | $39.3M | $50.8M | $30.7M | $38.9M | $45.5M |
| Liabilities | $10.2M | $10.4M | $10.1M | |||
| Assets | $42.3M | $49.7M | $60.9M | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $24.8M | $35.2M | $46.4M | $27.1M | $34.1M | $41.2M |
| Equity | $32.1M | $39.3M | $50.8M | $30.7M | $38.9M | $45.5M |
| Repayments Of Long Term Debt | $290.0K | $623.0K | ||||
| Retained Earnings Accumulated Deficit | -$279.6M | -$271.6M | -$255.9M | |||
| Property Plant And Equipment Net | $338.0K | $278.0K | $309.0K | |||
| Other Liabilities Noncurrent | $76.0K | $77.0K | $72.0K | |||
| Operating Lease Right Of Use Asset | $240.0K | $303.0K | $342.0K | |||
| Operating Lease Liability Current | $277.0K | $279.0K | $261.0K | |||
| Non Cash Lease Expense Adjustment | $9.0K | $11.0K | ||||
| Liabilities Current | $9.9M | $5.7M | $5.3M | |||
| Liabilities And Stockholders Equity | $42.3M | $49.7M | $60.9M | |||
| Inventory Net | $8.3M | $8.4M | $6.8M |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Share Based Compensation | $5.5M | $2.6M | $3.4M |
| Net Cash Provided By Used In Operating Activities | -$38.2M | -$23.5M | -$22.6M |
| Net Cash Provided By Used In Financing Activities | $41.1M | $54.7M | $1.8M |
| Net Cash Provided By Used In Investing Activities | -$242.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q1 2024 |
|---|---|---|
| Share Based Compensation | $989.0K | $767.0K |
| Net Cash Provided By Used In Operating Activities | -$8.3M | -$4.5M |
| Net Cash Provided By Used In Financing Activities | -$290.0K | $20.5M |
| Net Cash Provided By Used In Investing Activities |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 30.2M | 24.8M | 21.2M |
| Weighted Average Number Of Diluted Shares Outstanding | 30.2M | 24.8M | 21.2M |
| Earnings Per Share Diluted | $1.41 | $1.12 | $1.34 |
| Earnings Per Share Basic | $1.41 | $1.12 | $1.34 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 30.1M | 30.1M | 30.0M | 24.5M | 24.4M | 24.3M |
| Weighted Average Number Of Diluted Shares Outstanding | 30.1M | 30.1M | 30.0M | 24.5M | 24.4M | 24.3M |
| Earnings Per Share Diluted | $0.26 | $0.52 | $0.36 | $0.38 | $0.28 | $0.27 |
| Earnings Per Share Basic | $0.26 | $0.52 | $0.36 | $0.38 | $0.28 | $0.27 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Depreciation | $373.0K | $707.0K | $727.0K |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $5.5M | $2.6M | $3.4M |
| Foreign Currency Transaction Gain Loss Before Tax | -$2.1M | $3.8M | -$575.0K |
| Prepaid Expense And Deposits Current | $928.0K | $1.3M | $1.4M |
| Interest And Accretion Expense | $63.0K | $600.0K | $727.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|
| Depreciation | $93.0K | $102.0K | $116.0K | $164.0K | $184.0K | $199.0K |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $1.7M | $1.5M | $989.0K | $604.0K | $768.0K | $767.0K |
| Foreign Currency Transaction Gain Loss Before Tax | $935.0K | -$2.2M | $38.0K | -$410.0K | $520.0K | $870.0K |
| Prepaid Expense And Deposits Current | $195.0K | $365.0K | $718.0K | |||
| Interest And Accretion Expense | $48.0K | $169.0K |
Most recent annual filing with the SEC: March 5, 2026
Data sourced from SEC EDGAR public filings as of August 5, 2026.